Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced Annexin A1 Expression Associates with Disease Severity and Inflammation in Multiple Sclerosis Patients.
Colamatteo A, Maggioli E, Azevedo Loiola R, Hamid Sheikh M, Calì G, Bruzzese D, Maniscalco GT, Centonze D, Buttari F, Lanzillo R, Perna F, Zuccarelli B, Mottola M, Cassano S, Galgani M, Solito E, De Rosa V. Colamatteo A, et al. Among authors: bruzzese d. J Immunol. 2019 Oct 1;203(7):1753-1765. doi: 10.4049/jimmunol.1801683. Epub 2019 Aug 28. J Immunol. 2019. PMID: 31462505 Clinical Trial.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, Spitaleri DL, Iuliano G, Tedeschi G, Della Corte M, Bonavita S, Matarese G. Carrieri PB, et al. Among authors: bruzzese d. Metabolism. 2015 Sep;64(9):1112-21. doi: 10.1016/j.metabol.2015.05.001. Epub 2015 May 8. Metabolism. 2015. PMID: 25986733
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.
Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De Rosa V, Colamatteo A, Micillo T, De Luca Picione C, Saccà F, De Rosa A, Moccia M, Brescia Morra V, Matarese G. Lanzillo R, et al. Among authors: bruzzese d. Clin Immunol. 2017 Oct;183:249-253. doi: 10.1016/j.clim.2017.08.011. Epub 2017 Aug 18. Clin Immunol. 2017. PMID: 28823971
High levels of blood circulating immune checkpoint molecules in children with new-onset type 1 diabetes are associated with the risk of developing an additional autoimmune disease.
Bruzzaniti S, Piemonte E, Mozzillo E, Bruzzese D, Lepore MT, Carbone F, de Candia P, Strollo R, Porcellini A, Marigliano M, Maffeis C, Bifulco M, Ludvigsson J, Franzese A, Matarese G, Galgani M. Bruzzaniti S, et al. Among authors: bruzzese d. Diabetologia. 2022 Aug;65(8):1390-1397. doi: 10.1007/s00125-022-05724-3. Epub 2022 May 25. Diabetologia. 2022. PMID: 35610521
Progression of type 1 diabetes is associated with high levels of soluble PD-1 in islet autoantibody-positive children.
Bruzzaniti S, Piemonte E, Bruzzese D, Lepore MT, Strollo R, Izzo L, Di Candia F, Franzese A, Bifulco M, Mozzillo E, Ludvigsson J, Matarese G, Galgani M. Bruzzaniti S, et al. Among authors: bruzzese d. Diabetologia. 2024 Apr;67(4):714-723. doi: 10.1007/s00125-023-06075-3. Epub 2024 Jan 12. Diabetologia. 2024. PMID: 38214712 Free PMC article.
216 results